Recipharm Launches New Laboratory to Expand Analytical Services Offering
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced the completion of a new analytical laboratory at its facility in Bengaluru, India.
The new 370 m2 area is fully cGMP compliant and is equipped with state-of-the-art technology and instruments to cater for the rising demand from customers for the company’s stand-alone Recipharm Analytical Solutions.
Recipharm Analytical Solutions is designed to help customers with timely, reliable outsourced support for analytical services from concept through to commercial. The new laboratory will accommodate 40 scientists and will bolster the team’s capacity to support additional projects.
Ramesh Jagadeesan, PhD, Assistant Vice President, said “It’s great to be able to announce the inauguration of our new analytical laboratory under Recipharm Analytical Solutions. Despite all the challenges the pandemic has presented, our team has worked diligently to complete the project and ensure the laboratory is operational, on time.”
“We’re confident the new laboratory will bolster our ability to support our customers and meet their method development, validation and stability studies requirements while maintaining the quality services they’re accustomed to from Recipharm.”
Recipharm has also appointed Mr. Manivel Thangapragasam as Associate Director to lead the new laboratory. Manivel brings 21 years of experience in the field of analytical development and stability studies. Commenting on the appointment he said “I’m delighted to join the Recipharm team. Recipharm provides high quality analytical programmes and flexible capacity to customers when they need it. Given the speed the market is moving, it is clear that the demand for such services is on the rise.”
The new lab has been in full operation since August 1 2021.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com.
Total Page Views: 293